ALK and non-small cell lung carcinoma: Although there is enough evidence over the past 1–2 years supporting that plasma genotyping using hybrid-capture NGS technology can reliably detect fusions, such as ALK or ROS fusions in NSCLC patients [89], this analysis is not routinely performed on ctDNA.